Your browser doesn't support javascript.
loading
Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer.
Miyagi, Takehiro; Tsuji, Daiki; Kawasakai, Yohei; Ishikawa, Hiroshi; Tanaka, Rei; Nakao, Masahiko; Nakagaki, Shigeru; Hayashi, Toshinobu; Ayuhara, Hideaki; Harada, Tomohiko; Tamaki, Shinya; Maeda, Akimitsu; Ohashi, Yasukata; Arakawa, Yuichiro; Fujita, Yukiyoshi; Yamamoto, Keisuke; Miyamoto, Yasunori; Yano, Takuya; Itoh, Kunihiko.
Afiliación
  • Miyagi T; Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
  • Tsuji D; Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-ku, Shizuoka, 422-8526, Japan. d-tsuji@u-shizuoka-ken.ac.jp.
  • Kawasakai Y; Faculty of Nursing, Japanese Red Cross College of Nursing, Tokyo, Japan.
  • Ishikawa H; Department of Pharmacy, Shizuoka Cancer Center, Shizuoka, Japan.
  • Tanaka R; Department of Pharmacy, Shizuoka Cancer Center, Shizuoka, Japan.
  • Nakao M; Department of Pharmacy, Osaka City General Hospital, Osaka, Japan.
  • Nakagaki S; Department of Pharmacy, Shizuoka General Hospital, Shizuoka, Japan.
  • Hayashi T; Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.
  • Ayuhara H; Department of Pharmacy, Tokyo Medical University Hospital, Tokyo, Japan.
  • Harada T; Department of Pharmacy, Kanagawa Cancer Center, Kanagawa, Japan.
  • Tamaki S; Department of Pharmacy, KKR Sapporo Medical Center, Hokkaido, Japan.
  • Maeda A; Department of Pharmacy, Aichi Cancer Center Hospital, Aichi, Japan.
  • Ohashi Y; Department of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Arakawa Y; Department of Pharmacy, Tochigi Cancer Center, Tochigi, Japan.
  • Fujita Y; Division of Pharmacy, Gunma Prefectural Cancer Center, Gunma, Japan.
  • Yamamoto K; Department of Pharmacy, Seirei Hamamatsu General Hospital, Shizuoka, Japan.
  • Miyamoto Y; Department of Pharmacy, Hamamatsu Medical Center, Shizuoka, Japan.
  • Yano T; Department of Pharmacy, Sumitomo Besshi Hospital, Ehime, Japan.
  • Itoh K; Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
Eur J Clin Pharmacol ; 79(3): 407-414, 2023 Mar.
Article en En | MEDLINE | ID: mdl-36645467
PURPOSE: Chemotherapy-induced neutropenia (CIN) is a dose-limiting factor for cytotoxic chemotherapy, but recently, it was suggested that CIN contributes to prolonged survival. In this study, we examined the association between severe CIN and survival and determined whether CIN affected survival in patients with extensive-stage small cell lung cancer (ES-SCLC). METHODS: The medical records from 214 patients with ES-SCLC treated with etoposide or irinotecan in combination with cisplatin (EP/IP) between 2012 and 2016 were collected and retrospectively analyzed. Landmark analysis was performed at the end of cycle 4, and the relationship between severe CIN and survival was determined by a log-rank test. In addition, a multivariate analysis using the COX proportional hazard model was performed to identify independent predictive factors. The Landmark analysis included 102 patients in the IP group and 47 patients in the EP group. RESULTS: No significant difference was found between grades 0-3 and grade 4 neutropenia and overall survival (OS) in the EP group (P = 0.57). Contrariwise, for the IP patients, the median OS was 444 days for grades 0-3 and 633 days for grade 4 neutropenia, which was significantly longer for patients who developed grade 4 neutropenia (P = 0.03). Multivariate analysis adjusted for potential factors revealed that the development of grade 4 CIN was identified as a significant predictor of longer OS (hazard ratio [HR], 0.50; 95% confidence interval (CI), 0.28-0.87, P = 0.015). CONCLUSION: The results indicated that the development of severe CIN with IP therapy is associated with prolonged OS.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Pulmonar de Células Pequeñas / Neoplasias Pulmonares / Neutropenia / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Clin Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Pulmonar de Células Pequeñas / Neoplasias Pulmonares / Neutropenia / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Clin Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Alemania